<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886922</url>
  </required_header>
  <id_info>
    <org_study_id>Glibenclamide H-18052188</org_study_id>
    <nct_id>NCT03886922</nct_id>
  </id_info>
  <brief_title>The Hemodynamics Effect of Levcromakalim After Glibenclamide Administration Assessed by High Resolution Magnetic Resonance Angiography (MRA) Technique in a Randomized Double-blind Cross-over Placebo-controlled Study With Healthy Volunteers</brief_title>
  <official_title>The Hemodynamics Effect of Levcromakalim After Glibenclamide Administration Assessed by High Resolution MRA Technique in a Randomized, Double-blind, Cross-over and Placebo-controlled Study With Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of levcromakalim/placebo infusion on cranial arteries after
      glibenclamide administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      12 healthy participants will randomly be allocated to receive levcromakalim or placebo on to
      different days efter oral glibenclamide administration.

      The aim of the study is to investigate the effect of levcromakalim/placebo infusion on
      cranial arteries after glibenclamide administration.

      Repeated magnetic resonance angiography (MRA) measurements covering the middle meningeal
      artery (MMA), superficiel temporal artery (STA) and middle cerebral artery (MCA) before and
      after glibenclamide administration and levcromakalim/placebo infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, cross-over, placebo-controlled design in healthy volunteers.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the middle meningeal artery (MMA), superficiel temporal artery (STA) and middle cerebral artery (MCA)</measure>
    <time_frame>Time of measurements is baseline, 1 hour after glibenclamide administration, 2 hour after glibenclamide administration, 20 minutes after levcromakalim infusion, 60 min after levcromakalim infusion</time_frame>
    <description>Repeated MRA measurements covering the diameter of MMA , STA and MCA before and after glibenclamide administration and levcromakalim/placebo infusion measured by centimeter (cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Cerebral blood flow</measure>
    <time_frame>Time of measurements is baseline, 1 hour after glibenclamide administration, 2 hour after glibenclamide administration, 20 minutes after levcromakalim infusion, 60 min after levcromakalim infusion</time_frame>
    <description>Repeated MRA measurements covering the blood flow before and after glibenclamide administration and levcromakalim/placebo infusion measured by centimeter (cm)/minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Headache</measure>
    <time_frame>Time of headache measurements is from before (-10 min) and after (12 hours) glibenclamide administration.</time_frame>
    <description>Headache intensity will be recorded by numerical rating scale (NRS) from 0 to 10 (0, no headache; 1, a feeling of pressure; 10, worst imaginable headache).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hemodynamics of Cranial Arteries</condition>
  <condition>Headache</condition>
  <condition>Cerebral Blood Flow</condition>
  <arm_group>
    <arm_group_label>Glibenclamide and Levcromakalim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will recieve levcromakalim/placebo infusion after glibenclamide administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glibenclamide and Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive levcromakalim/placebo infusion after glibenclamide administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will receive levcromakalim/placebo infusion after glibenclamide administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levcromakalim</intervention_name>
    <description>Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.</description>
    <arm_group_label>Glibenclamide and Levcromakalim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.</description>
    <arm_group_label>Glibenclamide and Saline</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers of both sexes.

          -  18-60 years.

          -  50-100 kg.

          -  Women of childbearing potential must use adequate contraception

        Exclusion Criteria:

          -  A history of serious somatic disease

          -  Migraine or any other type of headache (except episodic tension-type headache less
             than once a month)

          -  Daily intake of any medication except contraceptives

          -  Contraindications for MRI scan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish headache center</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mohammad Al-Mahdi Al-Karagholi</name>
      <address>
        <city>KÃ¸benhavn S</city>
        <state>Danmark</state>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Mohammad Al-Mahdi Al-Karagholi</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cromakalim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

